PT-141

PT-141

Melanocortin Receptor Agonist Peptide

Also referenced as: Bremelanotide · PT-141 · Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH · Melanocortin Receptor Agonist

Most Popular
Best Value
Awaiting
Testing

≥99% Purity

Full Panel COA

UPS 2-Day Air

Shipment Insurance Included

Certificate Of Analysis

Awaiting Testing: Results Pending
TestResultStatus
Identity & Purity (Avg, HPLC + MS)Pending
Net Peptide Weight (Avg)Pending
Heavy Metals (ICP-MS)Pending
Endotoxins (LAL Assay)Pending
Sterility (DNA Microarray)Pending

Made in cGMP- and ISO-certified facilities our supply chain has vetted in person, then independently multi-lab tested by Virtus with a final Certificate of Analysis from ILS Laboratories. We pay more to source this way because we hold the highest standard for the product and for you.

View the full Certificate of Analysis →

PubMed Research

Curated research on PT-141

  • Molinoff PB (2003). PT-141: a melanocortin agonist for the treatment of sexual dysfunction Ann N Y Acad Sci.

    PMID: 12851303
  • Diamond LE (2006). An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist J Sex Med.

    PMID: 16839319

About PT-141

A cyclic heptapeptide analogue of α-melanocyte-stimulating hormone (α-MSH) investigated in preclinical research as a non-selective melanocortin receptor agonist. PT-141 is studied in receptor-pharmacology and animal-model work for its engagement of the melanocortin system, principally MC4R and MC3R, and the central signaling pathways associated with those receptors.

Derived from the melanotan II scaffold with a D-Phe substitution and an Asp–Lys lactam bridge that confer metabolic stability in laboratory assays, PT-141 (bremelanotide) is examined in published literature as a tool compound for probing melanocortin receptor selectivity, cAMP / Gs signaling, and hypothalamic melanocortin circuitry at the cellular level.

Also Referenced As

Bremelanotide · PT-141 · Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH · Melanocortin Receptor Agonist

Specifications

Scientific Name
PT-141: Bremelanotide (Melanocortin Receptor Agonist)
CAS Number
189691-06-3
Molecular Formula
C₅₀H₆₈N₁₄O₁₀
Molecular Weight
1,025.2 g/mol
Physical Form
Lyophilized powder
Purity
Coming Soon
Batch Number
TBD
Storage
−20°C, protected from light, avoid repeated freeze-thaw cycles

Storage & Handling

Lyophilized peptides remain stable for 12–24 months when stored properly. Follow standard laboratory protocols for handling.

Storage

Store lyophilized peptide at −20°C in a standard laboratory freezer, protected from light, moisture, and heat. Avoid repeated freeze-thaw cycles.

Shelf Life

Lyophilized form remains stable for 12–24 months at −20°C in the original sealed vial. Always reference the batch-specific COA for verified shelf-life data.

Mechanism & Research Background

PT-141 (bremelanotide) is a synthetic cyclic heptapeptide analogue of α-MSH with the structure Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH. In receptor-binding studies it behaves as a non-selective melanocortin receptor agonist, with highest reported affinity for MC4R and MC3R, intermediate activity at MC1R, and negligible activity at MC5R and MC2R. The D-Phe substitution and Asp–Lys lactam bridge are described in the literature as conferring resistance to enzymatic degradation in preclinical assays.

In cell-culture systems, melanocortin receptor engagement by PT-141 couples to Gs / adenylyl-cyclase / cAMP signaling, with Gq-linked phospholipase-C / Ca²⁺ and ERK / MAPK cascades also reported for MC4R. Published research uses the peptide as a reference melanocortin ligand for receptor-selectivity and signaling-pathway profiling, and as a centrally acting probe of hypothalamic melanocortin circuitry in animal models, distinct from peripheral vascular mechanisms.

MC4R is documented in rodent models as a regulator of energy homeostasis and appetite / satiety signaling, and PT-141 has been studied in this context as a melanocortin-pathway tool compound. The peptide is reported in preclinical literature to cross the blood–brain barrier, which has made it of interest for distinguishing central from peripheral melanocortin signaling. PT-141 remains a research-stage molecule; products supplied by Virtus Peptides are intended exclusively for in-vitro laboratory research and are not for human or animal use.